Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)

Table 1 Baseline patient characteristics by indigenous status at enrolment to the Australian HIV observational database

	Non-indigenous		Indigenous		Total
	(n = 2155)		(n = 42)		(N = 2197)
	n	%	n	%	n	%
Gender
Female	100	4.6	5	11.9	105	4.8
Male	2051	95.2	36	85.7	2087	95.0
Transgender	4	0.2	1	2.4	5	0.2
Reported HIV exposure category
Blood products	10	0.5	0	0.00	10	0.5
Heterosexual	170	7.9	8	19.1	178	8.1
IDU	51	2.4	3	7.1	54	2.5
MSM	1812	84.1	28	66.7	1840	83.8
MSM & IDU	60	2.8	1	2.4	61	2.8
Other	24	1.1	1	2.4	25	1.1
missing	28	1.3	1	2.4	29	1.3
Prior AIDS-defining condition
No	1777	82.5	38	90.5	1815	82.6
Yes	378	17.5	4	9.5	382	17.4
Geographical location of enrolling clinic
Metropolitan	1777	82.5	21	50.0	1798	81.8
Non-metropolitan	378	17.5	21	50.0	399	19.2
Antiretroviral therapy at enrolment
Naïve	562	26.1	14	33.3	576	26.2
Prior, not current, therapy	395	18.3	2	4.8	397	18.1
Current mono/dual therapy	76	3.5	1	2.4	77	3.5
3+ II,+/−NRTI,+/−NNRTI,+/−PI	16	0.7	0	0.0	100	4.6
3+ NNRTI + PI,+/−NRTI, No II	96	4.5	1	2.4	485	22.1
3+ NRTI + NNRTI, No PI, No II	545	25.3	13	31.0	562	25.6
3+ NRTI + PI, No NNRTI, No II	426	19.8	7	16.7	433	19.7
3+ NRTI, No PI, No NNRTI, No II	39	1.8	4	9.5	43	2.0
CD4 count at enrolment (cells per mm³)
<200	199	9.2	3	7.1	202	9.2
200-299	214	9.9	6	14.3	220	10.0
300-499	650	30.2	13	31.0	663	30.2
500+	989	45.9	18	42.9	1007	45.8
Missing	103	4.8	2	4.8	105	4.8
HIV viral load at enrolment (copies/ml))
≤400	1245	57.8	25	59.5	1270	57.8
401-10,000	339	15.7	5	11.9	344	15.7
>10,000	470	21.8	10	23.8	480	21.8
Missing	101	4.7	2	4.8	103	4.7

NRTI Nucleoside or nucleotide reverse transcriptase inhibitor, PI Protease inhibitor, NNRTI Non-nucleoside reverse transcriptase inhibitor, II Integrase inhibitor

ISSN: 1471-2334